BioNTech (NASDAQ:BNTX) Given a $150.00 Price Target by Wells Fargo & Company Analysts

BioNTech (NASDAQ:BNTX) received a $150.00 price objective from investment analysts at Wells Fargo & Company in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 34.71% from the company’s previous close.

A number of other equities analysts have also recently commented on BNTX. Citigroup reiterated a “buy” rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a report on Thursday, May 22nd. The Goldman Sachs Group started coverage on BioNTech in a research note on Thursday, May 29th. They set a “neutral” rating and a $110.00 price objective for the company. Wall Street Zen raised shares of BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, June 7th. Finally, Leerink Partners set a $112.00 price objective on shares of BioNTech in a research report on Monday, June 2nd. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $135.91.

BioNTech Stock Performance

Shares of BioNTech stock traded up $0.05 during trading hours on Tuesday, reaching $111.35. 891,767 shares of the stock traded hands, compared to its average volume of 698,142. The company has a 50 day moving average price of $109.08 and a 200 day moving average price of $106.23. The company has a quick ratio of 10.02, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $26.77 billion, a price-to-earnings ratio of -69.59 and a beta of 1.23. BioNTech has a one year low of $78.47 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million for the quarter, compared to analysts’ expectations of $161.26 million. During the same quarter last year, the firm posted ($3.36) EPS. The firm’s quarterly revenue was up 102.6% compared to the same quarter last year. On average, equities research analysts expect that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Banque Cantonale Vaudoise bought a new position in BioNTech in the first quarter worth about $36,000. LRI Investments LLC grew its stake in shares of BioNTech by 234.6% in the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after purchasing an additional 312 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in shares of BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after buying an additional 472 shares in the last quarter. Banque Transatlantique SA acquired a new position in shares of BioNTech in the 1st quarter valued at $80,000. Finally, Costello Asset Management INC purchased a new position in shares of BioNTech in the first quarter worth approximately $91,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.